Enterprise P&T Meeting Committee Meeting Minutes
February 4, 2019
Voting Members Present
Kirton Caton, MD Rogers Elebra, PharmD Chris Meny, PharmD Andrew Peterson, PharmD Wayne Weart, PharmD
Donald Beam, MD Gus, Geraci, MD Jay Messeroff, RPh Eric Peters, PharmD Rani Whitfield. MD
John Floyd Brinley, MD Glenn Hamilton, MD Kendra Michael, MD David Petkash, MD Rodney Wise, MD
William Burnham, MD Jeffrey Kreitman, PharmD Betty Muller Jeanine Plante, PharmD
Don Cooper, RPh Markus Kruesi, MD Lavdena Orr, MD Kirby Smith, MD
Excused Voting Members
Christopher Anypas, PharmD Jen Devinney, PharmD Karen Jordan, MD
David Batluck, DO Lily Higgins, MD Susan McAllister, MD
Invited Guests Present
Linda Albandoz, NCPhT - PRx Tracey Davis, PharmD Lanaye Lawyer, MD Patty Oaster, Administrative-
PRx
Melwyn Wendt, PharmD
Dustin Brookshire, Compliance
Manager
Fury Fecondo, PharmD Shalis. Lightner,
Pharmacy Manager
Brian O'Meara,
Administrative- PRx
Eric Weiss, PharmD
Patrick DeHoratius, PharmD-PRx Monica Guerriero, PharmD Lauren Megargell, PharmD-PRx Devon Trumbower, PharmD-
PRx
Kathleen Clement,
Administrative- PRx
April Holley, PharmD LDH Holly Moreau, PharmD Kyle Viator, Market
President
Michael Colvin, PharmD Paul Knecht, PharmD Michelle Murphy, PharmD
Pharmacy Director
Calla Vodoor – PharmD Prx
Issue Discussion Conclusion/Results Vote Action/ Person Responsible
1. Call to Order The meeting was called to order at 6:07 PM EST.
Dr. Burnham welcomed all external and internal
participants.
Informational Only
Dr. William Burnham
2. Conflict of Interest Disclosure
No conflicts announced
Informational Only
Dr. William Burnham
5. Review of last P&T Minutes
Jay Messeroff asked if there were any corrections or updates
to the minutes from August 06, 2018 PT meeting
Minutes approved
as presented
Unanimous
Jay Messeroff
6. Review and Approval of December Proxy Minutes
Minutes approved
as presented
Unanimous
Jay Messeroff
7. Old Business PerformRx
PerformRx
8. New Business
Fluphenazine
PerformRx makes the following recommendation:
For KF/AHC/AHNE/ : Make no changes to the formulary status of fluphenazine
at this time
Committee
approved as
recommended
Unanimous
. PerformRx will update the
criteria and formulary/PDL
with any changes
Choline product
additions to
formulary
PerformRx makes the following recommendation:
KF/AHC/ /AHN: Add Choline citrate 650mg tablet and Choline SR
300mg tablet to the formulary.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
9. Drug Reviews
Therapeutic Class
Calcitonin Gene-
related Peptide
(CGRP) Inhibitors
with PA Criteria
PerformRx makes the following recommendation:
KF/AHC/AHNE/ : 1. Add a quantity limit of 1 mL per 30 days for Aimovig
70 mg/mL Autoinjector (NDC 55513‐0841‐01), and 2 mL
per 30 days for Aimovig 140 mg dose Autoinjector 2 pack
(NDC 55513‐0841‐02)
a. Cost per month of treatment is equivalent for both
dose strengths only when the appropriate product is
dispensed. PerformRx recommends adding quantity
limits to ensure the appropriate product is dispensed.
2. Add Ajovy (fremanezumab‐vfrm) 225 mg/1.5 mL (GCN
45306) subcutaneous solution prefilled syringe to the
Specialty Tier with prior authorization.
3. Add Emgality 120 mg/mL Pen (GCN 40418, 40419) to
the Specialty Tier with prior authorization.
4. Update the prior authorization criteria to prefer Emgality
over the other agents in this class.
5. Approve the Calcitonin Gene‐Related Peptide (CGRP)
Receptor Antagonist criteria
a) Add Ajovy and Emgality to criteria
b) Prefer Emgality to other agents in this class.
c) Add age restriction according to package insert. d) Add references.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
First Generation
Antihistamines
PerformRx makes the following recommendations:
KF/AHC/AHNE/ 1. Remove carbinoxamine 4 mg/5 ml liquid (GCN 14949)
in an effort to align formularies within this class and
due to the availability of more cost effective alternatives
available within this class on the formulary
2. Remove chlorpheniramine (Chlorphen SR®) 12 mg
tablet, ER (OTC) (GCN 46541) in an effort to align
formularies within this class and due to a lack of
utilization and due to the availability of more cost
effective alternatives available within this class on the
formulary.
3. Remove chlorpheniramine (EdChloped Jr.®) 2 mg/5 ml
syrup (OTC) (GCN
46503) in an effort to align formularies within this
class and due to a lack of utilization and the
availability
of more cost effective alternatives available within
this class on the formulary.
4. Remove diphenhydramine 12.5 mg chewable tablet
(OTC) (GCN 46060) in an effort to align formularies
within this class and due to a lack of utilization and due
to the availability of more cost effective alternatives
available within this class on the formulary.
5. Remove diphenhydramine 12 mg/5 mL prefilled spoon
(OTC) (GCN 28478) in an effort to align formularies
within this class and due to a lack of utilization and the
availability of more cost effective alternatives available
within this class available on the formulary.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Platelet
Aggregation
Inhibitors
PerformRx makes the following recommendation:
KF/AHC/AHNE/ No changes are recommended at this time
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Benign Prostatic
Hyperplasia
PerformRx makes the following recommendation:
KF/AHC/AHNE/ : No changes are recommended at this time
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Pulmonary Arterial
Hypertension with
PA Criteria
PerformRx makes the following recommendation:
KF/AHC/AHNE : No changes to the formulary status of the medications
in this class
Approve the prior authorization criteria with the
changes recommended:
1. Add Tyvaso, Adempas and Ventavis to the initial 28
day approval as these medications require titration as
well
2. Streamline language for appropriate dosing
3. Clarify patient’s weight is only required for
medications with weight based dosing
4. Add Tyvaso and Ventavis to section requiring PDE-
5 and Letairis prior to approving these therapies.
Letairis and PDE-5 are recommended as first line
therapies for functional class 2 and 3 and are less
costly than the alternative therapies.
5. Combine functional class 2 and 3 requirements as
these classes are treated with the same therapies
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Cystic Fibrosis
with PA Criteria
PerformRx makes the following recommendation:
KF/AHC/AHNE/ Add sodium chloride for inhalation (Hyper‐Sal®,
Pulmosal™) 7% vial for nebulization to the
formulary. This is a low cost medication
recommended for all Cystic Fibrosis patients
regardless of severity and therefore should be
available without prior authorization as all prior
authorization requests are currently being approved.
Remove acetylcysteine 100 mg/ml and 200mg/ml vial
from the formulary. Due to the high cost of
acetylcysteine and insufficient evidence to
recommend for or against chronic use of inhaled or
oral acetylcysteine, PerformRx is recommending
removing this from the formulary. Additionally, there
is little to no utilization of this medication.
Approve the prior authorization criteria with no
changes.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Single Product
Reviews:
Methergine PerformRx makes the following
recommendation: KF/AHC/AHN/
No changes recommended
Committee
approved as
recommended
Unanimous
No Changes
New Products Reviews
PerformRx recommends to keep the following product remain non-formulary
KF/AHC/AHN/ Abilify Mycite
Aemcolo
Albuminex
Altreno
Arakoda
Bryhali
Cequa
Clorotekal
Demerol (PF) Carpuject
Epidiolex
Firdapse
Gamifant
Gleolan
Glyrx-PF
Inveltys
Lexette
Minolira
Nocdurna
Nuzyra
Omegaven
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes
Omnipaque
Oxervate
Panzyga
Promacta
Qbrexza
Recovi
Seysara
Siklos
Sympazan
Tegsedi
Tiglutik
Tirosint
Tolsura
Tresiba
Ultomiris
Xelpros
Xepi
Xerava
Xofluza
Xolair
Xyosted
Yupelri
Yutiq
Zortress
Ztlido
PerformRx recommends to keep the following products non-formulary and use drug specific PA criteria for
KF/AHC/AHN/ Actemra ACTPen
Ajovy
Azedra
Copiktra
Daurismo
Dupixent
Granix
Jivi
Khapzory
Libtayo
Lorbrena
Lumoxiti
Nivestym
Talzenna
Udenyca
Vitrakvi
Vizimpro
Xospata
PerformRx recommends to remain non- formulary for
KF/AHC/AHN/ Delstrigo
Pifeltro
PerformRx recommends to add to Specialty Tier and use drug specific PA criteria for:
KF/AHC/AHNE/ Arikayce
PerformRx recommends to add to specialty tier as preferred agent with drug specific PA criteria
KF/AHC/AHNE/
Emgality SQ Syringe
Embality SQ Pen
PerformRx recommends to add to Formulary with a quantity limit of 60 tablets per 30 days
KF/AHC/AHNE/ Xarelto
9. Prior Authorization Criteria Review
.
Prior Authorization
Criteria Annual
Review
Alpha-1 Proteinase
Inhibitors
PerformRx makes the following recommendation:
KF/AHC/AHN/ Approve the Alpha‐1 Proteinase Inhibitors (Human)
criteria for with the following changes
1. Addition of references
2. Listing preferred and non‐preferred agents to
enhance visibility
Unanimous
Tabled for next meeting
DDAVP PerformRx makes the following recommendation:
KF/AHC/AHNE/ Retire the DDAVP criteria
Remove prior authorization requirement from
desmopressin tablets and nasal spray/solution
Add a quantity limit of 90 tablets per 30 day for
desmopressin 0.1 mg tablets and a quantity limit of
180 tablets per 30 days for desmopressin 0.2 mg
tablets. Add a quantity limit of 15 mL per 30 days for
desmopressin 0.01% intranasal solution
Lower the minimum age limit for desmopressin
tablets to 4 years of age
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Diclegis PerformRx makes the following recommendation:
KF/AHC/AHN/ Add references Age restrictions according to package insert Clarify language Add Pyridoxine (vitamin B6) 25 mg tablet to the ACLA
formulary to ensure access to first line treatment for nausea and vomiting in pregnancy
.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Emflaza PerformRx makes the following recommendations: KF/AHC/AHNE/ Add references
Clarify when calcium and vitamin D supplementation is
required’
Add additional diagnostic confirmatory tests to align
with updated guidelines
Remove requirement for baseline behavioral health
evaluation
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Eosinophilic
Asthma Agents PerformRx makes the following recommendations:
KF/AHC/AHNE/ Addition of black box warning notification
Add references
Add Dupixent to drugs
Specified age restriction
Specified exclusion criteria prohibiting the use of
multiple monoclonal antibodies for the treatment of
asthma
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Gonadotropin
Releasing
Hormone Agonists
(GNRH)
PerformRx makes the following recommendations: KF/AHC/AHN/ Add references
Co‐preferring Zoladex, Lupron Depot, and Lupron
Depot‐Ped
Reformatted drug names
Remove Gonadotropin Releasing Hormone Antagonist
Firmagon from drug list
Add Lupaneta Pack to drug list
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes
Growth Hormones
PerformRx makes the following
recommendations: KF/AHC/AHN/ Genotropin removed due availability of Genotropin
Miniquick
Add specific criteria for growth failure in pediatrics
with CKD
Modify wording to specify all genetic diseases require
confirmatory testing
Separate adult and pediatric growth hormone deficiency
criteria
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes
Modify pediatric growth hormone deficiency criteria to
require GF‐1 and IGFBP‐3 together with severe
clinical/auxological features or, in their absence, GH
stimulation test
Remove requirement for 2 standard deviations below
mean for age in regard to height and bone age.
Hepsera PerformRx makes the following recommendations: KF/AHC/AHN/ Retire the Hepsera criteria and list as non-
formulary/Prior Authorization Required Medication
Ensure appropriate use and utilization of formulary
alternatives.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Hyaluronic Acid
Derivatives PerformRx makes the following recommendation:
KF/AHC/AHN/ Remove reference to capsaicin
List preferred and non-preferred agents to enhance
visibility
Add of TriVisc to non-preferred agents
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Add references
Injectable
Bisphosphonates &
Skeletal Related
Events
PerformRx makes the following recommendation: KF/AHC/AHN/ Modification to title
Require documentation of calcium and vitamin D
supplementation
Clarify CrCl requirements
Clarify use of denosumab and morbidity
Add endocrinologist to prescriber restrictions
.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
KF/AHC/AHN/ Remove Kynamro from the criteria as it has been
withdrawn from the market in the U.S
Add documentation of LDL level pre‐treatment in order
to assess efficacy for reauthorization
Add ezetimibe as a prerequisite requirement as it is
indicated for this diagnosis and has shown to be
efficacious
With the removal of Kynamro, Juxtapid is specifically
indicated for homozygous familial
hypercholesterolemia and therefore the diagnostic
criteria has been updated to reflect this
Ocaliva PerformRx makes the following recommendation: KF/AHC/AHN/ Removal of liver biopsy and ultrasound of the liver as
this is no longer required for diagnosis according to the
2018 AASLD guidelines
Minor language changes for clarification and ease of
review
Remove lipid panel requirements as decreases in HDL
due to Ocaliva should lead to consideration of benefits
vs risks and whether the medication should be
continued. Decreases do not warrant a denial of therapy
as this is not a contraindication and should be monitored
by and decided on by the prescriber.
Remove ALT/AST monitoring parameters and instead
require that patient does not have complete biliary
obstruction as this warrants permanent discontinuation
of therapy
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes
Opioid
Dependence
Agents
PerformRx makes the following recommendation: KF/AHC/AHN/ Remove requirement for negative pregnancy test
Remove requirement of monotherapy for pregnant
patients. New trial data show no difference in outcomes
between dual therapy vs monotherapy. Additionally,
buprenorphine monotherapy has shown a higher
potential for misuse. Choice of therapy should be
decided on by the provider.
Remove counseling requirements under reauthorization
section as new SAMHSA guidelines state that
counseling has not shown any added benefit and should
not be mandatory.
Remove urine drug screen requirements. ASAM
guidelines recommend utilizing urine drug screens as a
tool to support recovery rather than deny therapy.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Opioid containing
products PerformRx makes the following recommendation:
KF/AHC/AHN Add separate criteria for opioid cough and cold
products to differentiate from opioids requested for pain
Add criteria for reauthorization requests when doses
have increased since initial approval
Add non formulary statement into re-authorization
criteria
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Proprotein
Convertase
Subtilisin/Kexin 9
(PCSK9)
PerformRx makes the following recommendation: KF/AH/AHN Add trial of ezetimibe into Familial
Hypercholesterolemia section as a cost effective
alternative prior to treatment with a PCSK9 and in the
primary and secondary hyperlipidemia section as
recommended in the 2018 ACC/AHA guidelines
Changing criteria for “extreme risk” section to include
criteria for “high risk” and “very high risk” categories
according to 2018 ACC/AHA guidelines
Remove old treatment algorithm
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Spinraza PerformRx makes the following recommendation: KF/AHC/AHN/ Clarify that the first 5 dose approval is for initial requests
and the reauthorization approval will be for 3
maintenance doses allowing for one year of therapy.
Remove the lab parameters as these do not warrant a
denial of therapy.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Hepatitis C PerformRx makes the following recommendation:
KF/AHC/AHN/ : Add the newly approved generic Epclusa
(sofosbuvir/velpatasvir) and generic Harvoni
(ledipasvir/sofosbuvir) as preferred products
Update treatment summary charts to align with new AASLD guidelines and to include additional preferred
agents
Remove Zepatier dosing from renal impairment
treatment summary due to the addition of generic Epclusa
(sofosbuvir/velpatasvir) and generic Harvoni
(ledipasvir/sofosbuvir) which are preferred produc
Remove Vosevi from the genotype 3 treatment
experienced summary due to Vosevi being alternative
treatment and due to the addition of the preferred generic
Epclusa product for this subset of patients.
.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Specialty
Biological Agents
PerformRx makes the following recommendation:
Crohn’s Disease:
KF/AHC/AHN/ Stream the preferred vs non-preferred biologic language Move Inflectra to non-preferred. Add Pentasa as an option for prerequisite therapy as it is
indicated for Crohn’s Disease
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions.
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category.
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Ulcerative Colitis:
KF/AHC/AHN/ Streamlining preferred vs non-preferred biologic
language.
Move Inflectra to non-preferred.
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category.
Psoriasis:
KF/AHC/AHN/ Streamline preferred vs non-preferred biologic
language.
Move Inflectra to non-preferred
Move Cosentyx and Taltz to preferred
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions.
Change pre-requisites from one TNF to trial of two
preferred medications with different mechanisms of
action.
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category.
Approve requirement of only 1 pre-requisite
alternatives and 1 preferred biologic agent for ACLA to
align with state requirements
Polyarticular Juvenile Idiopathic Arthritis: KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions.
Change language of preferred TNF to preferred
"biologic" agent as many of our criteria now have
multiple mechanisms of actions in the preferred
product category
Approve requirement of only 1 pre-requisite alternative
and 1 preferred biologic agent for ACLA to align with
state requirements.
Systemic Juvenile Idiopathic Arthritis:
KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Remove new member criteria, allowing physician
attestation for new members who have taken NSAID
therapy already, and adding in more detailed continuation
of therapy/grandfathering provisions.
Addition of non-preferred biologic request criteria
Remove pediatric rheumatologist as rheumatologist in
general will capture this requirement.
Add more detailed continuation of therapy and
grandfathering provisions.
FDA (if no indication specific criteria) and NON-FDA Approved Medically Accepted Indications
KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Move Inflectra to non-preferred
Move Cosentyx, Taltz and Kevzara to preferred
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions.
Change pre-requisites to trial of three preferred
medications with different mechanisms of action.
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category
Approve requirement of only 1 pre-requisite alternative
and 1 preferred biologic agent to align with state
requirements
Rheumatoid KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Move Inflectra to non-preferred
Move Kevzara to preferred
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions.
Change pre-requisites to trial of two preferred
medications with different mechanisms of action.
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category
Approve requirement of only 1 pre-requisite alternative
and 1 preferred biologic agent to align with state
requirements
Ankylosing Spondylitis KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Move Inflectra to non-preferred
Move Cosentyx to preferred
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions
Change pre-requisites to trial of two preferred
medications with different mechanisms of action
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category
Approve requirement of only 1 pre-requisite alternative
and 1 preferred biologic agent for ACLA to align with
state requirements
Psoriatic Arthritis (PsA) KF/AHC/AHN/ Streamline preferred vs non-preferred biologic language
Move Inflectra to non-preferred
Move Cosentyx and Taltz to preferred
Remove new member criteria, allowing physician
attestation for new members who have taken
conventional therapy already, and adding in more
detailed continuation of therapy/grandfathering
provisions
Change pre-requisites to trial of two preferred
medications with different mechanisms of action
Change language of preferred TNF to preferred
“biologic” agent as many of our criteria now have
multiple mechanisms of actions in the preferred product
category
Approve requirement of only 1 pre-requisite alternative
and 1 preferred biologic agent for ACLA to align with
state requirements
Second Generation
Antihistamines PerformRx recommends approving the criteria for
with the following changes: KF/AHC/AHN/ Remove allegra (fexofenadine) from first line agents
and making non-formulary
Add 30 mg to Allegra (fexofenadine) as a non-
formulary agent for clarity
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Prior Authorization New Criteria:
Novoeight PerformRx makes the following recommendation: KF/AHC/AHN/ Approve the newly created criteria
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
Orilissa
PerformRx makes the following recommendation:
KF/AHC/AHN/ AHDE: Approve the new Orlissa criteria
Committee
approved as
recommended
Unanimous
PerformRx will update the
criteria and formulary/PDL
with any changes.
10. Recalls
There were several recalls in which members and providers
were notified.
Teva all Amlodipine/Valsartan Combination Tablets
and Amlodipine/Valsartan/Hydrochlorothiazide
Combination Tablets
Aurobindo 80 Lots of Amlodipine Valsartan Tablets,
Valsartan HCTZ Tablets, and Valsartan Tablets
Prinston Pharmaceutical- Irbesartan and Irbesartan
HCTZ Tablets
Torrent Pharmaceuticals recall of Losartan Potassium
Tablets
Sandoz recall of one lot of Losartan Potassium and
Hydrochlorothiazide
Mylan recall of 15 Lots of Valsartan Tablets,
Amlodipine and Valsartan Tablets, and Valsartan and
Hydrochlorothiazide Tablets
Informational
Melissa
Jeff Kreitman
Affected members
who had prescriptions filled
for these
products were all notified
11. Adjournment
The meeting adjourned at 7:18 PM EST
N/A
William
Burnham
The next meeting April 29,
2019 from 6:00 PM‐ 8:00
PM.
________________________________ __4/18/2019_____________
Dr. Glenn Hamilton, MD - Chair Date